NVO:NYSE
Novo Nordisk A/S
$43.07
arrow_downward
-2.14%(-0.94) 1D
$43.57
arrow_upward
+1.16% (+0.50)todayPre-market
Closed: Sep 11, 4:00:09 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVO...
Open
$43.20
High
$43.50
Low
$42.72
Mkt. cap
147.84B
Avg. vol.
12.89M
Volume
135.11K
Dividend
4.17%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
10.60
52-wk high
$64.16
52-wk low
$35.12
EPS
$4.06
Beta
0.73
Shares outstanding
3.39B
No. of employees
67K
Open
$43.20
High
$43.50
Low
$42.72
Mkt. cap
147.84B
Avg. vol.
12.89M
Volume
135.11K
Dividend
4.17%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
10.60
52-wk high
$64.16
52-wk low
$35.12
EPS
$4.06
Beta
0.73
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
WSJ
·
13 minutes ago
Novo Nordisk Slims Down Name to Novo
GuruFocus
·
35 minutes ago
Is NVO Undervalued? DCF Says Worth $91
Benzinga
·
1 hour ago
Novo Nordisk Just Dropped ‘Nordisk’ From Its Name as Obesity Drug Battle With Eli Lilly Heats Up — Here’s Why
Sharecast.com
·
1 hour ago
Novo Nordisk rebrands as ‘Novo’ as it unveils new company identity
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7K
FoundedDec 21, 1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com